Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 17 studies | 37% ± 16% | |
eye | 9 studies | 31% ± 11% | |
lung | 8 studies | 23% ± 8% | |
kidney | 6 studies | 32% ± 10% | |
heart | 4 studies | 34% ± 6% | |
liver | 4 studies | 33% ± 18% | |
adipose | 4 studies | 34% ± 25% | |
pancreas | 3 studies | 47% ± 27% | |
intestine | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 39538.74 | 2641 / 2642 | 99% | 121.22 | 695 / 705 |
kidney | 100% | 11284.06 | 89 / 89 | 97% | 77.89 | 876 / 901 |
prostate | 95% | 5349.31 | 233 / 245 | 97% | 49.78 | 487 / 502 |
thymus | 99% | 6612.54 | 646 / 653 | 89% | 26.43 | 540 / 605 |
breast | 98% | 7244.05 | 449 / 459 | 83% | 25.89 | 929 / 1118 |
lung | 99% | 6967.49 | 573 / 578 | 81% | 19.45 | 935 / 1155 |
esophagus | 81% | 3572.84 | 1172 / 1445 | 97% | 30.33 | 177 / 183 |
adrenal gland | 99% | 6536.69 | 256 / 258 | 73% | 13.22 | 169 / 230 |
stomach | 91% | 5649.29 | 328 / 359 | 79% | 22.47 | 227 / 286 |
ovary | 77% | 2765.13 | 138 / 180 | 82% | 19.53 | 352 / 430 |
liver | 91% | 5440.72 | 206 / 226 | 59% | 10.97 | 239 / 406 |
pancreas | 73% | 2768.68 | 241 / 328 | 74% | 13.70 | 132 / 178 |
intestine | 69% | 2774.18 | 663 / 966 | 71% | 15.16 | 374 / 527 |
skin | 50% | 4344.84 | 903 / 1809 | 88% | 27.18 | 417 / 472 |
bladder | 95% | 4007.67 | 20 / 21 | 36% | 7.37 | 183 / 504 |
uterus | 86% | 3690.14 | 147 / 170 | 43% | 8.11 | 198 / 459 |
muscle | 100% | 9114.81 | 800 / 803 | 0% | 0 | 0 / 0 |
adipose | 98% | 8263.81 | 1175 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 35.56 | 78 / 80 |
heart | 92% | 9368.67 | 794 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 90% | 5567.96 | 1205 / 1335 | 0% | 0 | 0 / 0 |
spleen | 89% | 4095.71 | 214 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 47% | 7.40 | 21 / 45 |
peripheral blood | 46% | 3646.74 | 424 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 4.69 | 8 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030511 | Biological process | positive regulation of transforming growth factor beta receptor signaling pathway |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0007628 | Biological process | adult walking behavior |
GO_0050882 | Biological process | voluntary musculoskeletal movement |
GO_0060059 | Biological process | embryonic retina morphogenesis in camera-type eye |
GO_0007224 | Biological process | smoothened signaling pathway |
GO_2000059 | Biological process | negative regulation of ubiquitin-dependent protein catabolic process |
GO_0008283 | Biological process | cell population proliferation |
GO_0048596 | Biological process | embryonic camera-type eye morphogenesis |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0032092 | Biological process | positive regulation of protein binding |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0030878 | Biological process | thyroid gland development |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0030578 | Biological process | PML body organization |
GO_0001654 | Biological process | eye development |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0030182 | Biological process | neuron differentiation |
GO_0051402 | Biological process | neuron apoptotic process |
GO_0097193 | Biological process | intrinsic apoptotic signaling pathway |
GO_0060395 | Biological process | SMAD protein signal transduction |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_0060425 | Biological process | lung morphogenesis |
GO_0003016 | Biological process | respiratory system process |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0009952 | Biological process | anterior/posterior pattern specification |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0060235 | Biological process | lens induction in camera-type eye |
GO_0061072 | Biological process | iris morphogenesis |
GO_0010467 | Biological process | gene expression |
GO_0006468 | Biological process | protein phosphorylation |
GO_0040029 | Biological process | epigenetic regulation of gene expression |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0010842 | Biological process | retina layer formation |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0016604 | Cellular component | nuclear body |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0046332 | Molecular function | SMAD binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0046790 | Molecular function | virion binding |
Gene name | HIPK2 |
Protein name | Homeodomain-interacting protein kinase 2 (hHIPk2) (EC 2.7.11.1) Homeodomain interacting protein kinase 2 Alternative protein HIPK2 |
Synonyms | tcag7.426 |
Description | FUNCTION: Serine/threonine-protein kinase involved in transcription regulation, p53/TP53-mediated cellular apoptosis and regulation of the cell cycle. Acts as a corepressor of several transcription factors, including SMAD1 and POU4F1/Brn3a and probably NK homeodomain transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1, ZBTB4 and DAZAP2. Inhibits cell growth and promotes apoptosis through the activation of p53/TP53 both at the transcription level and at the protein level (by phosphorylation and indirect acetylation). The phosphorylation of p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the response to hypoxia by acting as a transcriptional co-suppressor of HIF1A. Mediates transcriptional activation of TP73. In response to TGFB, cooperates with DAXX to activate JNK. Negative regulator through phosphorylation and subsequent proteasomal degradation of CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase activity. Activates CREB1 and ATF1 transcription factors by phosphorylation in response to genotoxic stress. In response to DNA damage, stabilizes PML by phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. Promotes angiogenesis, and is involved in erythroid differentiation, especially during fetal liver erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300 transcription regulation activity. Triggers ZBTB4 protein degradation in response to DNA damage. In response to DNA damage, phosphorylates DAZAP2 which localizes DAZAP2 to the nucleus, reduces interaction of DAZAP2 with HIPK2 and prevents DAZAP2-dependent ubiquitination of HIPK2 by E3 ubiquitin-protein ligase SIAH1 and subsequent proteasomal degradation . Modulates HMGA1 DNA-binding affinity. In response to high glucose, triggers phosphorylation-mediated subnuclear localization shifting of PDX1. Involved in the regulation of eye size, lens formation and retinal lamination during late embryogenesis. . |
Accessions | H7BXX9 ENST00000428878.6 [Q9H2X6-3] Q9H2X6 ENST00000406875.8 [Q9H2X6-1] A4D1R9 ENST00000342645.7 L8ECJ8 |